A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
NCT ID: NCT00002377
Last Updated: 2017-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
1997-01-31
2002-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
NCT00002330
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
NCT00002222
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
NCT00017784
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes
NCT00001062
A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir
NCT00000970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Valganciclovir
Ganciclovir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed peripheral CMV retinitis
* More than 3 weeks of previous therapy for CMV retinitis
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of California / Irvine
Irvine, California, United States
Univ of California / San Diego / Dept of Pediatrics
La Jolla, California, United States
Univ of California / San Diego Treatment Ctr
San Diego, California, United States
Davies Med Ctr / Institute for HIV Research
San Francisco, California, United States
Kaiser Permanente Med Ctr
San Francisco, California, United States
QUEST Clinical Research
San Francisco, California, United States
Dr Alan Palestine
Washington D.C., District of Columbia, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Emory Eye Clinic
Atlanta, Georgia, United States
New England Med Ctr
Boston, Massachusetts, United States
New York Univ Med Ctr
New York, New York, United States
St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis
New York, New York, United States
New York Hosp - Cornell Med Ctr
New York, New York, United States
Duke Univ Eye Ctr
Durham, North Carolina, United States
Austin Infectious Disease Consultants
Austin, Texas, United States
St Pauls Hosp
Vancouver, British Columbia, Canada
The Toronto Hosp / Dept of Infectious Disease
Toronto, Ontario, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Royal Victoria Hosp
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WV15376
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.